Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer: A Multicenter Phase 2 Trial

IMPORTANCE: Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation–positive non–small cell lung cancer is well established, optimal dosing remains to be established, especially in elderly or frail patients. OBJECTIVE: To investigate the efficacy a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Autores principales: Miyamoto, Shingo, Azuma, Koichi, Ishii, Hidenobu, Bessho, Akihiro, Hosokawa, Shinobu, Fukamatsu, Nobuaki, Kunitoh, Hideo, Ishii, Mari, Tanaka, Hiroshi, Aono, Hiromi, Nakahara, Yoshiro, Kusaka, Kei, Hosomi, Yukio, Kikuchi, Norihiro, Mori, Yoshiaki, Itani, Hidetoshi, Hamada, Akinobu, Yamada, Kazuhiko, Okamoto, Hiroaki
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7226294/
https://ncbi.nlm.nih.gov/pubmed/32407455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.1250
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares